According to an announcement dated 4 February 2026, WuXi XDC Cayman Inc. (the “Company,” Stock Code: 2268), together with WuXi Biologics (Cayman) Inc. and BioDlink International Company Limited, referenced a joint announcement made on 14 January 2026 regarding proposals (the “Offers”). The Company notes that the making of the Offers and relevant share acquisitions were approved by the controlling shareholder, WuXi Biologics (Cayman) Inc., which holds more than 50% of the Company’s issued share capital, thereby exempting the need for a general meeting.

The Company earlier anticipated despatching a circular (“Circular”) on or before 4 February 2026 containing additional details on the Offers, acquisition of the Offer Shares, and recommendations from the board. Additional time was required to prepare and finalize information to be included in the Circular. The Company applied to the Stock Exchange for a waiver from Rule 14.41(a) of the Listing Rules, and the Circular’s despatch date is postponed to on or before 13 February 2026. On 4 February 2026, the Stock Exchange granted this waiver with the understanding that the Circular would be dispatched by that date, subject to potential change if circumstances alter.

The current board of the Company comprises three executive directors, three non-executive directors, and three independent non-executive directors. The executive directors are Dr. Jincai Li (also Chief Executive Officer), Mr. Jerry Jingwei Zhang, and Mr. Xiaojie Xi. The non-executive directors are Dr. Zhisheng Chen, Dr. Jijie Gu, and Ms. Ming Shi. The independent non-executive directors are Dr. Ulf Grawunder, Mr. Kenneth Walton Hitchner III, and Mr. Hao Zhou.